

## ASX ANNOUNCEMENT

20 June 2023

### Cann signs significant variation with key customer for supply to 31 December 2023

---

- Cann signs 6-month oil supply deal worth approximately \$0.88 million with key existing customer;
  - Cann to supply dried flower and oil from its state-of-the-art facility in Mildura;
- 

**20 June 2023** – Cann Group Limited (ASX: CAN) (**Cann** or the **Company**) is pleased to announce that it has signed a variation agreement with Levin Health Pty Ltd (“**Levin**”) for the supply of medicinal cannabis products from 1 July 2023 to 31 December 2023 (“**supply period**”).

Cann expects to supply oils worth approximately \$880,000 to meet Levin’s production schedule over the supply period. Additionally, Cann will also continue to supply flower products in line with the customer’s needs over the supply period.

Cann CEO Peter Koetsier said “*Securing longer-term supply agreements with our preferred partners is a critical component for our company’s strategic success. Cann recognises the importance of establishing stable and reliable supply chains using our TGO93 compliant cultivation and production facility to meet the evolving demands of our customers. Through this, we believe we can enhance our competitive advantage and position ourselves as a trusted and dependable partner in the industry.*”

The parties will meet during the supply period to determine order quantities for the second half of financial year 2024.

**Authorised for release by Deborah Ambrosini, Company Secretary, Cann Group Limited.**

**For all other information please contact:**

Peter Koetsier  
CEO  
Cann Group Limited  
+61 3 9095 7088  
[contact@canngrouplimited.com](mailto:contact@canngrouplimited.com)

Deborah Ambrosini  
CFO and Company Secretary  
Cann Group Limited  
+61 3 9095 7088  
[deborah.ambrosini@canngrouplimited.com](mailto:deborah.ambrosini@canngrouplimited.com)

#### About Cann Group

Cann Group Limited (ABN 25 603 949 739) is enhancing patients’ lives by developing, producing, and supplying innovative cannabis medicines. The Company has built world-class research, cultivation and GMP manufacturing facilities in Melbourne, and a state-of-the-art large-scale cultivation and GMP manufacturing facility near Mildura, Victoria. Cann Group supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. Cann Group also owns Satipharm and its patent-protected capsule technology.

Learn more at: [www.canngrouplimited.com](http://www.canngrouplimited.com) | [www.satipharm.com](http://www.satipharm.com)